Ikarian Capital’s Gilead Sciences GILD Stock Holding History

Ikarian Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-181,300	Closed	-$10.8M	–	163
2022 Q1	$10.8M	Buy	+181,300	New	+$11.6M	1.42%	20

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ikarian Capital's GILD Position: Q3 2020 in Review

Ikarian Capital sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 6,218 shares — an estimated $478K sold.

Ikarian Capital first reported a position in GILD in Q2 2020 and held it in 1 quarter. The position peaked at $478K in Q2 2020. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

Ikarian Capital reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
Ikarian Capital sold 6,218 Gilead Sciences shares in Q3 2020, an estimated $478K.
Ikarian Capital first reported a position in Gilead Sciences in Q2 2020 and held it in 1 quarter.
Ikarian Capital's Gilead Sciences position peaked at $478K in Q2 2020.
1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.